Search Results - "Alesh, Issa"

Refine Results
  1. 1
  2. 2

    Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure by Beemath, Afzal, Stein, Paul D., Skaf, Elias, Al Sibae, M. Rasm, Alesh, Issa

    Published in The American journal of cardiology (15-09-2006)
    “…Because of uncertainty about the prevalence of pulmonary embolism (PE) and deep venous thrombosis (DVT) in hospitalized patients with congestive heart failure…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Effect of Long-term Monotherapy with the Aldosterone Receptor Blocker Eplerenone on Cytoskeletal Proteins and Matrix Metalloproteinases in Dogs with Heart Failure by RASTOGI, Sharad, MISHRA, Sudhish, ZACA, Valerio, ALESH, Issa, GUPTA, Ramesh C, GOLDSTEIN, Sidney, SABBAH, Hani N

    Published in Cardiovascular drugs and therapy (01-12-2007)
    “…Long-term monotherapy with the aldosterone receptor blocker eplerenone in dogs with HF was previously shown to improve LV systolic and diastolic function. This…”
    Get full text
    Journal Article
  5. 5

    Mortality from acute pulmonary embolism according to season by Stein, Paul D, Kayali, Fadi, Beemath, Afzal, Skaf, Elias, Alnas, Majd, Alesh, Issa, Olson, Ronald E

    Published in Chest (01-11-2005)
    “…Varying observations have been made on seasonal differences of mortality from acute pulmonary embolism (PE). The number of deaths each year from PE, from 1980…”
    Get more information
    Journal Article
  6. 6

    Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis by Briasoulis, Alexandros, Mallikethi-Reddy, Sagar, Palla, Mohan, Alesh, Issa, Afonso, Luis

    Published in Heart (British Cardiac Society) (01-09-2015)
    “…Late gadolinium enhancement (LGE) on cardiac MRI that indicates the extent of myocardial fibrosis in hypertrophic cardiomyopathy (HCM) is a potential risk…”
    Get more information
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19

    Long (>12 Months) and Short (<6 Months) Versus Standard Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Systematic Review and Meta-Analysis by Palla, Mohan, Briasoulis, Alexandros, Siddiqui, Fayez, Alesh, Issa, Afonso, Luis

    Published in American journal of therapeutics (01-07-2017)
    “…Dual antiplatelet therapy (DAPT) is recommended for 6-12 months after drug-eluting stent (DES) implantation to prevent ischemic events and late stent…”
    Get full text
    Journal Article
  20. 20

    ASSOCIATION OF NON-HIGH DENSITY LIPOPROTEIN-CHOLESTEROL WITH CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR EVENS IN MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS by Briasoulis, Alexandros, Siddiqui, Fayez, Alesh, Issa, Kottam, Anupama, Afonso, Luis

    “…After adjustments for age, sex, race, systolic blood pressure, anti-hypertension medications, smoking, diabetes, lipid lowering therapy, triglycerides, and…”
    Get full text
    Journal Article